Scholarlink

<p>The treatment of lung cancer is currently not adapted to patient sex. However, accumulating evidence from lung cancer trials and meta-analyses suggest that clear differences exist between men and women, particularly regarding the optimal treatment of non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors. In Germany, both immune checkpoint inhibitors alone and immunochemotherapies are approved to treat patients with NSCLC without driver mutations and with high PD-L1 expression ≥ 50 %. In several trials of immunotherapy alone compared to standard chemotherapy in first line, male patients had a numerically greater advantage, whereas women profited more from the addition of an immune checkpoint inhibitor to chemotherapy. Results of clinical trials comparing immunotherapy with checkpoint inhibitors alone to Immunochemotherapy in female and male patients have not yet been generated.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nicht-kleinzelliges Lungenkarzinom: Ist geschlechtsspezifische Immuntherapie nötig?

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月23日

查看全文
  • Eva Krieghoff-Henning,
  • Maike Collienne,
  • Sonja Loges

摘要

The treatment of lung cancer is currently not adapted to patient sex. However, accumulating evidence from lung cancer trials and meta-analyses suggest that clear differences exist between men and women, particularly regarding the optimal treatment of non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors. In Germany, both immune checkpoint inhibitors alone and immunochemotherapies are approved to treat patients with NSCLC without driver mutations and with high PD-L1 expression ≥ 50 %. In several trials of immunotherapy alone compared to standard chemotherapy in first line, male patients had a numerically greater advantage, whereas women profited more from the addition of an immune checkpoint inhibitor to chemotherapy. Results of clinical trials comparing immunotherapy with checkpoint inhibitors alone to Immunochemotherapy in female and male patients have not yet been generated.